Danofloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Danofloxacin
DrugBank Accession Number
DB11393
Background

Danofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.

Type
Small Molecule
Groups
Experimental, Vet approved
Structure
Weight
Average: 357.385
Monoisotopic: 357.148869679
Chemical Formula
C19H20FN3O3
Synonyms
  • Danofloxacin
  • Danofloxacine
  • Danofloxacino
  • Danofloxacinum
External IDs
  • A180

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Danofloxacin mesylate94F3SX3LEM119478-55-6APFDJSVKQNSTKF-FXMYHANSSA-N
International/Other Brands
Advocin

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Aminoquinolines and derivatives / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines / N-alkylpyrrolidines
show 14 more
Substituents
1,4-diazinane / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid
show 32 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
24CU1YS91D
CAS number
112398-08-0
InChI Key
QMLVECGLEOSESV-RYUDHWBXSA-N
InChI
InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1
IUPAC Name
1-cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
[H][C@]12CN(C3=C(F)C=C4C(=O)C(=CN(C5CC5)C4=C3)C(O)=O)[C@]([H])(CN1C)C2

References

General References
  1. Haritova AM, Rusenova NV, Parvanov PR, Lashev LD, Fink-Gremmels J: Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys. Vet Res Commun. 2006 Oct;30(7):775-89. [Article]
  2. Hubschle O, Godinho K, Rowan T, Nicholas R: Danofloxacin treatment of cattle affected by CBPP. Vet Rec. 2004 Sep 25;155(13):403. [Article]
  3. Froshauer S, Silvia AM, Chidambaram M, Sharma B, Weinstock GM: Sensitization of bacteria to danofloxacin by temperate prophages. Antimicrob Agents Chemother. 1996 Jun;40(6):1561-3. [Article]
  4. Ramezani AM, Manzoori JL, Amjadi M, Jouyban A: Spectrofluorimetric determination of human serum albumin using terbium-danofloxacin probe. ScientificWorldJournal. 2012;2012:940541. doi: 10.1100/2012/940541. Epub 2012 May 2. [Article]
  5. Goudah A, Mouneir SM: Disposition kinetics and tissue residues of danofloxacin in Muscovy ducks. Br Poult Sci. 2009 Sep;50(5):613-9. doi: 10.1080/00071660903147416. [Article]
  6. el-Gendi AY, el-Banna HA, Abo Norag M, Gaber M: Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. Dtsch Tierarztl Wochenschr. 2001 Oct;108(10):429-34. [Article]
  7. McKellar QA, Gibson IF, McCormack RZ: Pharmacokinetics and tissue disposition of danofloxacin in sheep. Biopharm Drug Dispos. 1998 Mar;19(2):123-9. [Article]
  8. Chen Y, Rosazza JP, Reese CP, Chang HY, Nowakowski MA, Kiplinger JP: Microbial models of soil metabolism: biotransformations of danofloxacin. J Ind Microbiol Biotechnol. 1997 Nov-Dec;19(5-6):378-84. [Article]
  9. Atef M, El-Gendi AY, Aziza, Amer MM, Abd El-Aty AM: Some pharmacokinetic data for danofloxacin in healthy goats. Vet Res Commun. 2001 Jul;25(5):367-77. [Article]
KEGG Drug
D07774
ChemSpider
64439
RxNav
1358488
ChEMBL
CHEMBL157548
ZINC
ZINC000000607798
Wikipedia
Danofloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.738 mg/mLALOGPS
logP0.33ALOGPS
logP0.71Chemaxon
logS-2.7ALOGPS
pKa (Strongest Acidic)5.65Chemaxon
pKa (Strongest Basic)6.73Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area64.09 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity95.47 m3·mol-1Chemaxon
Polarizability36.6 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0009000000-e048be0db694a270fa5b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0039000000-2de08119d97b88fca8ad
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0091000000-675182ffe7305734ecbf
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0009000000-0fae04470d5a0a44b48c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-0069000000-869e107f9987fb58e015
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0009000000-98be2f14136f49e59785
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0009000000-80ae0fb15c976486582a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-056u-0059000000-971725abbae1f460e552
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00xr-0093000000-a62c437647eee3ad0ae0
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-185.64442
predicted
DeepCCS 1.0 (2019)
[M+H]+188.0024
predicted
DeepCCS 1.0 (2019)
[M+Na]+194.76427
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:22 / Updated at April 30, 2021 13:08